Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 47: 803-804, 2001;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sacks, D. B.
Right arrow Articles by Lernmark, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sacks, D. B.
Right arrow Articles by Lernmark, A.
Related Collections
Right arrow Clinical Immunology
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2001;47:803-804.)
© 2001 American Association for Clinical Chemistry, Inc.

Editorial

Molecular Manipulation of Autoantibody Testing in Type 1 Diabetes: Two for One

David B. Sacks1a and Ake Lernmark2

1 Department of Pathology, Brigham and Women’s Hospital, and, Harvard Medical School, Boston, MA 02115

2 Department of Medicine, University of Washington, Seattle, WA 98195

aAddress correspondence to this author at: Brigham and Women’s Hospital, Thorn 530, 75 Francis St., Boston, MA 02115. Fax 617-278-6921; e-mail dsacks@rics.bwh.harvard.edu.

Diabetes mellitus is an epidemic that, according to estimates, will have a prevalence of 5.4% of the global population by the year 2025 (1). The number of adults with diabetes in the world is expected to rise from 135 million in 1995 to 300 million by 2025. Although the majority of the escalation will be attributable to type 2 diabetes, the prevalence of type 1 diabetes is also increasing. Data pooled from 27 countries reveal that the incidence of type 1 diabetes is rising by 3% per year (2), predominantly in children and young adults. In addition, several studies report that ~10% of type 2 diabetes patients have islet autoantibody markers of type 1 diabetes, which predict insulin dependency (3)(4). Because the number of patients classified with type 2 diabetes is 10- to 20-fold greater than those deemed to have type 1 diabetes, this group of possible slow-onset type 1 diabetes is likely to have a significant impact on the severity of the diabetes epidemic.

Despite advances in diabetes treatment and monitoring that permit improved glycemic control, insulin therapy is inadequate to prevent patients from developing eye, kidney, nerve, and cardiovascular disease. Moreover, tight control, which cannot be achieved by all patients, is associated with a substantially increased risk of hypoglycemia (5). A desirable goal in the management of diabetes is to prevent the disease before clinical onset. Although several strategies aimed at prevention are under evaluation (6)(7), this will be attained only if type 1 diabetes can be diagnosed before the appearance of clinical . . . [Full Text of this Article]


References




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. DiabetesHome page
W. E. Winter, N. Harris, and D. Schatz
Immunological Markers in the Diagnosis and Prediction of Autoimmune Type 1a Diabetes
Clin. Diabetes, October 1, 2002; 20(4): 183 - 191.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Association for Clinical Chemistry.